Efinopegdutide 20 mg/mL
6024-001
Phase 2 small_molecule completed
Quick answer
Efinopegdutide 20 mg/mL for Nonalcoholic Fatty Liver Disease is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Nonalcoholic Fatty Liver Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed